Skip to main content
. 2017 Oct 20;18(11):904–915. doi: 10.1080/15384047.2017.1385678

Figure 3.

Figure 3.

Aberrant HN1L expression indicated the malignant proliferation. (a) Knockdown of HN1L inhibited cell proliferation measured by BrdU incorporation assay. Scale bar, 50 μm. Data represent mean ± SD. *P < 0.05. (b) IHC staining showed the low-proportion of proliferative cells in tumor produced from HN1L silenced cells. Scale bar, 50 μm. Data represent mean ± SD. *P < 0.05. (c) The IC50 values of paclitaxel and cisplatin for A549 and HCC827 cells with or without HN1L silencing. Data represent mean ± SEM. *P < 0.05.